Navigation Links
Scoliosis: An Unnatural Curve
Date:5/11/2008

Treatment includes watchful waiting, bracing and, sometimes, surgery,,,,

SUNDAY, May 11 (HealthDay News) -- Human spines are naturally curved and flexible so that you can bend, twist, reach and more.

But, in some people, the natural curve of the spine doesn't develop properly and the spine takes on an "S" or "C" shape.

This condition is known as scoliosis and it affects about 6 million Americans, according to the National Scoliosis Foundation. While it isn't a dangerous or life-threatening condition, it can sometimes be uncomfortable. And for teens, it can be damaging to self-esteem.

"Scoliosis still carries a black cloud over it, but for the vast majority of children, it doesn't matter and they grow up fine," said Dr. John Grayhack, an attending physician and orthopaedic surgeon at Children's Memorial Hospital in Chicago.

Scoliosis is usually diagnosed between the ages of 10 and 15, according to the scoliosis foundation. If you have a family member who's had scoliosis, your odds of developing the disorder increase to one in five, instead of the usual one in 50, according to the American Academy of Orthopaedic Surgeons .

In most cases, the cause of scoliosis isn't known. However, there are two known causes of scoliosis: congenital and neuromuscular, according to the U.S. National Institutes of Health. In congenital scoliosis, a problem occurs in the womb when the spine is forming that causes it to develop with a curve. In neuromuscular scoliosis, the curve may be caused by poor muscle control or weakness from diseases such as cerebral palsy or muscular dystrophy. The muscles simply can't keep the spine in proper alignment. Later in life, scoliosis may occur as a result of osteoporosis.

Many children are unaware they have scoliosis. It's often discovered during a routine physical exam or at a scoliosis screening at school. Signs of scoliosis include a spine curving abnormally to the si
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2008)...ma Database Manager Server is chosen as the embedd...ar business process management software. , ... 2008 -- Birdstep Technology (OSE: BIRD), which of...es, today announced that that uTraxx selected RDM ...nagement software. , ,"uTraxx.net is a softw...
(Date:11/22/2008)...t is now happening for Medicare Advantage Plans. ..., and may also include Part D Prescription Drug Co...r instant quotes and applications. , ...2008 -- MediGap Advisors is pleased to announce op...dicare Advantage Plans are health plan options tha...
(Date:11/21/2008)...ogether to stop abusive behavior, experts say , ...vior that was once dismissed as "kids being kids" ...g research shows the negative effects on both the ... schools, parents and even kids themselves are com...havior. , "Bullying shouldn,t be considered a ...
(Date:11/21/2008)...ewswire/ -- During a memorial service in the Capi...embered Lieutenant Governor Catherine Baker Knoll ...lic service, and a tireless advocate for the peopl...elected lieutenant governor, Catherine was a noted...l. "Her family and her faith were driving forces i...
Breaking Medicine News(10 mins):Health News:uTraxx Selects Birdstep Technology's RDM Server for its Next Generation Business Process Management Software 2Health News:uTraxx Selects Birdstep Technology's RDM Server for its Next Generation Business Process Management Software 3Health News:MediGap Advisors Announces Open Enrollment for Medicare Supplement Plans 2Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3
...in evaluating people's risk factors for heart dise...ls, beginning at age 20, the American Heart Associ... prevention of heart attack and stroke. Thomas Pea...disease actually begins in teenage years,// and th...
...avored cod liver oil followed by a chewy, multi-vi... ear infections in children. New studies show chil... required fewer antibiotics and had fewer ear infe...plements and cod liver oil, which has vitamins A a...
...hormone suppression therapy could increase substan...es of living free of the disease.Michel Bolla, a p... the potential benefits of suppressing the male ho...n male hormone testosterone, among 400 patients in...
...ications can reduce abdominal fat in people with t...exas have been looking into the effect that the dr....// They studied 10 people with the condition, who...s time body weight had, on the whole, increased. B...
Other Medicine News:Health News:Heart attack risk starts at 20 2Health News:Hormone Therapy applicable for Prostate Cancer 2
(Date:11/20/2008)...nical data from a prospective,registry presented ... DVT,treatment with the Trellis(R) Peripheral Inf...lara, CA) successfully breaks up the blood clot in... technique, called isolated pharmacomechanical thr...afely than current catheter-directed thrombolysis,...
(Date:11/20/2008)...wswire/ -- The Scandinavian-based drug,developmen... studies on its,lead antimicrobial candidate LTX-...udies showed that the novel lytic peptidomimetic h...ntly better towards killing Staphylococcus,aureus...ndard drugs. In,addition to this it has proven ef...
(Date:11/19/2008)...swire-FirstCall/ -- Amgen,(Nasdaq: AMGN ) and M...ry of,Takeda Pharmaceutical Company Limited (TSE:...ase 3 MONET1 trial evaluating motesanib (AMG 706) ...r the first-line treatment of,advanced non-small ...ended,following a planned safety data review of 6...
(Date:11/19/2008)...ings on critical enzyme,s regulation may hold key ...isorders , , MEMPHIS, Tenn., Nov. 19 /PRNew...ren,s Research Hospital have gained new insights i...ses called calpains. , , As the cell,s mol...llular processes, including the movement of cells ...
Breaking Medicine Technology:Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Research Triangle Area Health Care Collaborative Launches Bridges to Excellence 28R 29 Initiative to Improve Quality and Lower Costs 24 1Research Triangle Area Health Care Collaborative Launches Bridges to Excellence 28R 29 Initiative to Improve Quality and Lower Costs 24 2Research Triangle Area Health Care Collaborative Launches Bridges to Excellence 28R 29 Initiative to Improve Quality and Lower Costs 24 3Research Triangle Area Health Care Collaborative Launches Bridges to Excellence 28R 29 Initiative to Improve Quality and Lower Costs 24 4Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo 28TM 29 Program 19 1Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo 28TM 29 Program 19 2Indevus Receives Approvable Letter From FDA for VALSTAR 28R 29 for Bladder Cancer Therapy 14 1Indevus Receives Approvable Letter From FDA for VALSTAR 28R 29 for Bladder Cancer Therapy 14 2Indevus Receives Approvable Letter From FDA for VALSTAR 28R 29 for Bladder Cancer Therapy 14 3Indevus Receives Approvable Letter From FDA for VALSTAR 28R 29 for Bladder Cancer Therapy 14 4Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect Protected Corn Trait 9 1Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect Protected Corn Trait 9 2
...point of Improvement in Overall,Survival, WESTMINS...-,Allos Therapeutics, Inc. today announced top lin... 3 study of Efaproxyn ,(efaproxiral) plus whole br...etastases originating from breast cancer. The stud...trating a,statistically significant improvement in...
... /PRNewswire-FirstCall/ -- Quigley,Pharma, <a targ...www.QuigleyPharma.com , a wholly,owned subsidiary ...,has completed a follow-up study to evaluate the i...tokine Interleukin-6 (IL-6) in a,cachexia model. T...wer levels of serum IL-6 when administered QR-443 ...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Second Successful Quigley QR-443 Study Suggests Method of Action,Relevant to Broad Range of Chronic Inflammatory Diseases - Human,Study to Follow - 2Second Successful Quigley QR-443 Study Suggests Method of Action,Relevant to Broad Range of Chronic Inflammatory Diseases - Human,Study to Follow - 3Second Successful Quigley QR-443 Study Suggests Method of Action,Relevant to Broad Range of Chronic Inflammatory Diseases - Human,Study to Follow - 4
The series SV stereomicroscopes are of the single-objective (telescope) type. Thanks to their mature modular design they optimally adapt to the job in hand. This is an advantage which users of demand
10:1 Zoom Ratio - The parallel optical system of the SMZ-1000 has a 10:1 zoom with clickstops at 1X intervals. It features a zoom range of 0.8X to 8.0X and total magnification (depending on eyepieces
With a zoom ratio of 15:1, a zoom range of 0.75X to 11.25X, and the convenience of clickstops at 1X intervals from 1X to 11X, observation becomes easier than ever. Magnifications of 3.75X to 540X can
Inquire
Medicine Products: